A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies
Phase 1/2 Recruiting
80 enrolled
Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
Phase 1/2 Recruiting
233 enrolled
Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients
Phase 1/2 Recruiting
64 enrolled
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
Phase 1/2 Recruiting
182 enrolled
A Phase I/II Study of Zotiraciclib for Recurrent Malignant Gliomas With Isocitrate Dehydrogenase 1 or 2 (IDH1 or IDH2) Mutations
Phase 1/2 Recruiting
96 enrolled
MK-9999-01C
Phase 1/2 Recruiting
50 enrolled
Application of [68Ga]Ga-NI-FAPI-04 PET/CT Imaging in Fibroblast Activation Protein Related Diseases
Phase 1/2 Recruiting
30 enrolled
EMPOWER
Phase 1/2 Recruiting
65 enrolled
TumorGlow Intraoperative Molecular Imaging (IMI)
Phase 1/2 Recruiting
500 enrolled
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
Phase 1/2 Recruiting
616 enrolled
A Clinical Study to Test if an Investigational Treatment Called BNT314 When Used in Combination With Another Investigational Treatment BNT327 and Chemotherapy, is Beneficial and Safe for Patients With Advanced Colorectal Cancer
Phase 1/2 Recruiting
482 enrolled
ADORATION
Phase 1/2 Recruiting
46 enrolled
MK-3475-G21
Phase 1/2 Recruiting
20 enrolled
PIKALO-1
Phase 1/2 Recruiting
720 enrolled
Safety, PK, and Preliminary Efficacy of MBRC-101 in Advanced Refractory Solid Tumors
Phase 1/2 Recruiting
130 enrolled
ARTACUS
Phase 1/2 Recruiting
90 enrolled
Two Part Study of Nenocorilant Combined With Nivolumab in Patients With Advanced Solid Malignancies
Phase 1/2 Recruiting
50 enrolled
Carbon Nanoparticle-Loaded Iron in the Treatment of Advanced Solid Tumor
Phase 1/2 Recruiting
54 enrolled
LiFFT
Phase 1/2 Recruiting
63 enrolled
A Study to Assess Adverse Events and Change in Disease Activity of Oral ABBV-453 Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
Phase 1/2 Recruiting
130 enrolled
Pembrolizumab, Ibrutinib and Rituximab in PCNSL
Phase 1/2 Recruiting
37 enrolled
EVEREST-2
Phase 1/2 Recruiting
474 enrolled
A Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors (MK-3120-002)
Phase 1/2 Recruiting
270 enrolled
ACTengine
Phase 1/2 Recruiting
375 enrolled
SELECT-CAR-NK
Phase 1/2 Recruiting
85 enrolled
EBNK-ST-001
Phase 1/2 Recruiting
83 enrolled
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion Alone or in Combination With Oral, IV, Subcutaneous Daratumumab; Lenalidomide; Dexamethasone; Carfilzomib
Phase 1/2 Recruiting
440 enrolled
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
Phase 1/2 Recruiting
460 enrolled
An Open Label Dose Finding Study of PTT-4256 in Patients With Solid Tumours (RAISIC-1).
Phase 1/2 Recruiting
30 enrolled
Clinical Application of Al18F-NOTA-FAPI-04 PET/CT or PET/MRI Imaging in Malignant Tumor,Cardiovascular or Immune Disease
Phase 1/2 Recruiting
600 enrolled
Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma
Phase 1/2 Recruiting
90 enrolled
Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors
Phase 1/2 Recruiting
361 enrolled
ELECTRA
Phase 1/2 Recruiting
73 enrolled
Study of Ifinatamab Deruxtecan (DS-7300a, I-DXd) in Participants With Advanced Solid Malignant Tumors
Phase 1/2 Recruiting
250 enrolled
A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
Phase 1/2 Recruiting
796 enrolled
Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent Cancer
Phase 1/2 Recruiting
90 enrolled
Phase 1/2 Study of IMC-R117C in Selected Advanced Cancers
Phase 1/2 Recruiting
600 enrolled
A Study of LM-350 in Subjects With Advanced Solid Tumours
Phase 1/2 Recruiting
80 enrolled
Phase I/II Clinical Study of SHR-1501 Combined With Adbelizumab in Patients With Malignant Tumors
Phase 1/2 Recruiting
203 enrolled
ESMART
Phase 1/2 Recruiting
472 enrolled
A First-in-Human, JAB-8263 in Adult Patients With Advanced Tumors
Phase 1/2 Recruiting
152 enrolled
A Study of YL242 in Subjects With Advanced Solid Tumors
Phase 1/2 Recruiting
424 enrolled
DAHLIA
Phase 1/2 Recruiting
85 enrolled
Study of GV20-0251 in Participants With Solid Tumor Malignancies
Phase 1/2 Recruiting
350 enrolled
A Phase Ib/II Clinical Trial of LBL-007 Combined With Tislelizumab in the Treatment of Malignant Tumors
Phase 1/2 Recruiting
490 enrolled
Transarterial Chemoembolization (TACE) Plus Bevacizumab for Liver Metastases
Phase 1/2 Recruiting
40 enrolled
Tumorad
Phase 1/2 Recruiting
90 enrolled
IMA402 T Cell-Engaging Receptor Molecule (TCER®) in Recurrent and/or Refractory Solid Tumors
Phase 1/2 Recruiting
145 enrolled
P300
Phase 1/2 Recruiting
252 enrolled
KYANITE-1
Phase 1/2 Recruiting
250 enrolled